Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 15 06 2020
revised: 14 12 2020
accepted: 20 12 2020
pubmed: 3 1 2021
medline: 23 3 2021
entrez: 2 1 2021
Statut: ppublish

Résumé

Urgent action is needed to fight the ongoing coronavirus disease 2019 (COVID-19) pandemic by reducing the number of infected cases, contagiousness and severity. Chlorpromazine (CPZ), an antipsychotic from the phenothiazine group, is known to inhibit clathrin-mediated endocytosis and has antiviral activity against severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus. The aim of this in-vitro study was to test CPZ against SARS-CoV-2 in monkey and human cells. Monkey VeroE6 cells and human alveolar basal epithelial A549-ACE2 cells were infected with SARS-CoV-2 in the presence of various concentrations of CPZ. Supernatants were harvested at day 2 and analysed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) for the presence of SARS-CoV-2 RNA. Cell viability was assessed in non-infected cells. CPZ was found to have antiviral activity against SARS-CoV-2 in monkey VeroE6 cells, with a half maximal inhibitory concentration (IC Although the measured SI values are low, the IC These preclinical findings support clinical investigation of the repurposing of CPZ, a drug with mild side effects, in the treatment of patients with COVID-19.

Identifiants

pubmed: 33387629
pii: S0924-8579(20)30502-1
doi: 10.1016/j.ijantimicag.2020.106274
pmc: PMC7772996
pii:
doi:

Substances chimiques

Antiviral Agents 0
Chlorpromazine U42B7VYA4P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106274

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Eur J Pharmacol. 1976 Dec;40(2):263-72
pubmed: 991935
Br J Clin Pharmacol. 2016 Feb;81(2):199-209
pubmed: 26374633
Int J Biol Sci. 2020 Mar 15;16(10):1724-1731
pubmed: 32226290
J Pharm Pharmacol. 1995 Sep;47(9):782-90
pubmed: 8583393
Sci Rep. 2018 May 8;8(1):7268
pubmed: 29740149
Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):247-55
pubmed: 6519126
J Virol. 2006 Jul;80(14):6964-72
pubmed: 16809302
Expert Rev Hematol. 2019 Mar;12(3):195-205
pubmed: 30793644
Life Sci. 1983 Nov 14;33(20):2025-31
pubmed: 6645788
Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
pubmed: 24841273
Psychiatry Res. 1979 Jul;1(1):23-9
pubmed: 317844
J Virol. 2020 Oct 14;94(21):
pubmed: 32817221
J Neurol. 2020 Jul;267(7):1880-1882
pubmed: 32361836
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
Arch Gen Psychiatry. 1981 Feb;38(2):202-7
pubmed: 7212947
J Virol. 2007 Aug;81(16):8722-9
pubmed: 17522231
J Cell Biol. 1993 Dec;123(5):1107-17
pubmed: 8245121
PLoS One. 2011;6(12):e28923
pubmed: 22205980
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
J Natl Cancer Inst. 2019 Jul 1;111(7):646-654
pubmed: 30753567
J Virol. 2008 Aug;82(16):8112-23
pubmed: 18550663
J Support Oncol. 2013 Mar;11(1):8-13
pubmed: 23137588
PLoS Pathog. 2014 Nov 06;10(11):e1004502
pubmed: 25375324
PLoS Negl Trop Dis. 2018 Aug 9;12(8):e0006685
pubmed: 30092029
Acta Virol. 1982 Jul;26(4):209-16
pubmed: 6127927
Virology. 2018 May;518:301-312
pubmed: 29574335
J Virol. 2000 Mar;74(5):2288-92
pubmed: 10666259
Ann Med Psychol (Paris). 1952 Jun;110(2 1):112-7
pubmed: 12986408
J Gen Virol. 2003 Jul;84(Pt 7):1737-1741
pubmed: 12810867
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62
pubmed: 28910830
Encephale. 2020 Jun;46(3S):S35-S39
pubmed: 32387014
Biochem Pharmacol. 1968 Oct;17(10):2061-70
pubmed: 5696876
Adv Exp Med Biol. 2006;581:309-12
pubmed: 17037550
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
pubmed: 24841269
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Traffic. 2015 Jun;16(6):635-54
pubmed: 25693808
PLoS One. 2018 Mar 22;13(3):e0194868
pubmed: 29566060
Headache. 2015 Jan;55(1):3-20
pubmed: 25600718
Obstet Gynecol. 2018 Jan;131(1):e15-e30
pubmed: 29266076

Auteurs

Marion Plaze (M)

GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Université de Paris, Paris, France.

David Attali (D)

GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Université de Paris, Paris, France; Physics for Medicine Paris, INSERM, ESPCI Paris, CNRS, PSL Research University, Université Paris Diderot, Sorbonne Paris Cite, Paris, France.

Matthieu Prot (M)

Institut Pasteur, G5 Evolutionary Genomics of RNA Viruses, Paris, France.

Anne-Cécile Petit (AC)

GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Institut Pasteur, Experimental Neuropathology Unit, Paris, France.

Michael Blatzer (M)

Institut Pasteur, Experimental Neuropathology Unit, Paris, France.

Fabien Vinckier (F)

GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Université de Paris, Paris, France.

Laurine Levillayer (L)

Institut Pasteur, Functional Genetics of Infectious Diseases Unit, Paris, France.

Jeanne Chiaravalli (J)

Institut Pasteur, Chemogenomic and Biological Screening Core Facility, C2RT, Paris, France.

Florent Perin-Dureau (F)

Fondation Rothschild, Department of Anaesthesiology, ASMR-II Consulting, Regstem, Paris, France.

Arnaud Cachia (A)

Université de Paris, Laboratoire de Psychologie du développement et de l'Education de l'Enfant, CNRS, Paris, France; Université de Paris, Institut de Psychiatrie et Neurosciences de Paris, INSERM, Paris, France.

Gérard Friedlander (G)

Université de Paris, Paris, France.

Fabrice Chrétien (F)

Université de Paris, Paris, France; Institut Pasteur, Experimental Neuropathology Unit, Paris, France; GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte-Anne, Service de Neuropathologie, Paris, France.

Etienne Simon-Loriere (E)

Institut Pasteur, G5 Evolutionary Genomics of RNA Viruses, Paris, France.

Raphaël Gaillard (R)

GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Université de Paris, Paris, France; Institut Pasteur, Experimental Neuropathology Unit, Paris, France. Electronic address: r.gaillard@ghu-paris.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH